Each of the three trials had two co-primary endpoints, one for satisfying sexual events (SSEs) and the other for sexual desire. Each of the 3 trials also had a secondary endpoint that measured distress related to sexual desire. All three trials showed that flibanserin produced an increase in the number of SSEs and reduced distress related to sexual desire. The first two trials used an electronic diary to measure sexual desire, and did not find an increase. These two trials also measured sexual desire using the Female Sexual Function Index (FSFI) as a secondary endpoint, and an increase was observed using this latter measure. The FSFI was used as the co-primary endpoint for sexual desire in the third trial, and again showed a statistically significant increase.Womens overall feeling of improvement was small to none. The overall quality of the evidence was low. Side effects
Adverse events are more common among women taking flibanserin. The majority of adverse events were mild to moderate. The most commonly reported adverse events included dizziness, nausea, feeling tired, sleepiness, and trouble sleeping.Drinking alcohol while on flibanserin may result in severely low blood pressure (low blood pressure that produced symptoms after two glasses of wine occurred in 17%).
Novolin is the brand name of three distinct insulin-containing products manufactured by Novo Nordisk:

Novolin 70/30, an insulin preparation containing mixed NPH and regular insulin, respectively
Novolin N, an insulin preparation containing NPH insulin
Novolin R, an insulin preparation containing regular insulin

See also
Insulin (medication)


== References ==